Side effects and perceptions among young adults in Bangladesh following COVID-19 vaccination: a single center study

IMC Journal of Medical Science, Год журнала: 2024, Номер unknown, С. 1 - 11

Опубликована: Июль 31, 2024

Background and objectives: COVID-19, caused by SARS-CoV-2, has led to a global pandemic with severe health, economic, social impacts. Vaccination emerged as crucial mitigation strategy. Despite the pivotal role of COVID-19 vaccines in controlling pandemic, vaccine hesitancy remains significant concern globally, particularly among young adults. This study aimed explore side effects perceptions adults Bangladesh following vaccination. Materials methods: The study, conducted April 2021 325 Bangladeshi who received two doses Sinopharm (BBIBP-CorV) against SAR-CoV-2. Participants completed self-administered online questionnaire covering demographics, health history, post-vaccination adverse events, about vaccine. A symptom scoring system, based on interquartile range (IQR), was used categorize severity effects. Data analysis utilized SPSS version 26.0, appropriate tests for significance. Result: Total participants (male - 64.6%, female 68.9%) were enrolled. mean age 22 ± 1.6 years. Social media (43·1%) primary source information COVID-19. Vaccine related experienced 40.9% 47.1% 1st 2nd dose vaccination respectively. Side more prevalent after second vaccine, females (31·3% vs. 8·2%, p<0·001). Common included fatigue (41·6%), injection site pain/swelling (36·7%) headache (32·6%). In over 50% participants, symptoms appeared within 8 hours both doses. Symptoms resolved taking rest at home majority participants. comorbidity reported significantly higher rate first (61.8% 37·3%, p <0.05). effects, 69·8% felt reassured post-vaccination, 63·7% believed its long-term safety, 98·8% recommended others. Conclusion: well-tolerated Bangladesh. Though observed yet most maintained positive perception, underscoring acceptability July 2024; Vol. 18(2):011. DOI:https://doi.org/10.55010/imcjms.18.023 *Correspondence: Md. Faizul Ahasan, Department Pharmacology, Ibrahim Medical College, 1/A Sarani, Segunbagicha, Dhaka 1000, Email: [email protected]

Язык: Английский

---

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial

Human Vaccines & Immunotherapeutics, Год журнала: 2022, Номер 18(6)

Опубликована: Ноя. 28, 2022

Previous phase I to III clinical trials have shown that the inactivated SARS-CoV-2 vaccine namely CoronaVac has good efficacy, safety, and immunogenicity. This IV trial aims evaluate lot-to-lot consistency, immunogenicity, safety on a commercial scale in healthy adults, which could provide data support stable manufacturing. In this single-center, randomized, double-blind study, 1,080 adults aged 26-45 years were randomly assigned into three groups receive one of lots vaccines. All subjects received two doses with an interval 28 days. Serum samples collected before first dose days after second assess Solicited local systemic adverse events (AEs) within 7 unsolicited AEs each vaccination recorded. A total 1,039 participants completed study included per-protocol set (PPS). The GMTs 75.2 (68.5,82.6), 65.0 (59.0,71.7), 65.3 (59.4,71.8), respectively, seroconversion rates neutralizing antibody all higher than 98%. GMT ratios pair 1.16 (1.01,1.32), 1.15 (1.01, 1.32), 0.99 (0.87, 1.14), meeting immunological equivalence criteria. incidence reactions (ARs) 19.17%, 13.89%, 18.33%, no statistical difference. ARs grade 1 2, incidences 15.46% 2.50%. Non-vaccine-related serious (SAEs) reported. These results showed robust safety. production indicated is suitable for large-scale use.Trial registration number: NCT04894227 (ClinicalTrials.gov).

Язык: Английский

---

Prevalence and Risk Factors of Adverse Effects and Allergic Reactions after COVID-19 Vaccines in a Mexican Population: An Analytical Cross-Sectional Study

Vaccines, Год журнала: 2022, Номер 10(12), С. 2012 - 2012

Опубликована: Ноя. 25, 2022

Vaccinations have helped to control the COVID-19 pandemic; however, few studies focus on adverse effects and allergic reactions of these vaccines fewer a scope in Latin American population. The objective this study was assess associations between vaccinations, sex, age, reactions, effects. This an analytical cross-sectional conducted 1 July October 2022. sample consisted 443 surveyed participants, with total 1272 vaccine doses. Seven (Pfizer BioNTech, Oxford-AstraZeneca, CanSino, Moderna, Johnson Johnson, Sinovac, Sputnik V) were evaluated. A 12.6% those had at least one reaction posterior vaccination, females greater chance developing (p < 0.001, OR 3.1). most common chest pain, Pfizer-BioNTech Oxford-AstraZeneca associated onset 0.005). 54.6% developed effects, which myalgia, fever, cephalea, asthenia or adynamia, arthralgia; moreover, older age 0.5). concludes that BNT162b2 BioNTech) ChAdOX1 nCOV-19 (Oxford-AstraZeneca) are strongly ORs 1.6 (CI 95%, 1.18 2.3) 1.87 1.35 2.6), respectively. In addition, there relation found prevalence comorbidities, after infection vaccination.

Язык: Английский

---

Adverse Effects Reported and Insights Following Sinopharm COVID-19 Vaccination

Current Microbiology, Год журнала: 2023, Номер 80(12)

Опубликована: Окт. 20, 2023

Язык: Английский

---

Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico

Vaccines, Год журнала: 2022, Номер 10(8), С. 1196 - 1196

Опубликована: Июль 27, 2022

After emergency authorization, different COVID-19 vaccines were administered across Mexico in 2021, including mRNA, viral vector, and inactivated platform vaccines. In the state of Baja-California, 3,516,394 doses administered, 2285 adverse events (AE) registered epidemiological surveillance system 2021. Incidence rates per 100,000 calculated for total, mild (local systemic), severe AE each vaccine. Symptoms compared between mRNA vector/inactivated virus The overall incidence rate all was 64.98 doses; 79.05 vaccines; 56.9 vaccine platforms. at least five times higher recipients AstraZeneca from Serum Institute India (AZ SII). Local injection site symptoms more common while systemic prevalent Severe similar (0.72-1.61 doses), except AZ SII, which documented 12.6 doses. Among 32 hospitalized cases, 28 (87.5%) discharged. Guillain-Barré Syndrome most serious reported (n = 7). Adverse differed among manufacturers but consistent with clinical trials population-based reports literature.

Язык: Английский

---

A Mobile App Leveraging Citizenship Engagement to Perform Anonymized Longitudinal Studies in the Context of COVID-19 Adverse Drug Reaction Monitoring: Development and Usability Study

JMIR Human Factors, Год журнала: 2022, Номер 9(4), С. e38701 - e38701

Опубликована: Авг. 2, 2022

Over the past few years, studies have increasingly focused on development of mobile apps as complementary tools to existing traditional pharmacovigilance surveillance systems for improving and facilitating adverse drug reaction (ADR) reporting.In this research, we evaluated potentiality a new app (vaxEffect@UniMiB) perform longitudinal studies, while preserving anonymity respondents. We applied monitor ADRs during COVID-19 vaccination campaign in sample Italian population.We administered vaxEffect@UniMiB convenience academic subjects vaccinated at Milano-Bicocca University hub national campaign. was developed both Android iOS devices. The asks users send their medical history and, upon every vaccine administration, data that occurred within 7 days postvaccination, making it possible follow ADR dynamics each respondent. sends over web an application server. server, along with receiving all user data, saves SQL database server reminds patients submit by push notifications sent through Firebase Cloud Messaging (FCM). On initial startup app, unique identifier (UUID) generated respondent, so its completely ensured, enabling studies.A total 3712 people were first wave. A 2733 (73.6%) respondents between ages 19 80 coming from (UniMiB) Politecnico Milan (PoliMi), participated survey. Overall, collected information about dose 2226 (60.0% vaccinated), second 1610 (43.4% nonsponsored fashion, third 169 individuals (4.6%).vaxEffect@UniMiB revealed be attempt performing same subject time terms reported after guaranteeing complete subject. series aspects contributed positive involvement using report vaccination: ease use, availability multiple platforms, survey participants protection submitted health care workers' support.

Язык: Английский

---

Side effects after COVID-19 vaccination: a comparison between the most common available vaccines in Iran

Iranian Journal of Microbiology, Год журнала: 2023, Номер unknown

Опубликована: Апрель 16, 2023

Background and Objectives: Since the coronavirus disease 2019 (COVID-19) pandemic began, several vaccines have been manufactured to subside it. This study aimed determine prevalence of side effects after injecting common COVID-19 available in Iran. Materials Methods: cross-sectional was accomplished on Shahid Beheshti University Medical Sciences (Tehran, Iran) employees during January September 2022. Eligible participants were selected based simple ran- dom method interviewed about vaccine. Results: The mean age 656 38.03 ± 9.53 years, 453 (69.1%) female. post-vac- cination higher receiving first dose (53.2%) than second (35.9%) third (49.4%) doses. Across all three vaccine doses, overall proportion following AstraZeneca others. most effect myalgia (41.9%), followed by fever (36.6%), chills (31.6%), local reactions (27.0%), headache (25.5%), sweating (21.6%). People experienced mainly (23.3%) (20.3%) Additionally, had (37.2%), (30.8%), (29.2%), (26.0%), (24.4%) Conclusion: a post-vaccination adverse Sputnik V, Pastocovac, Sin- opharm. flu-like syndrome at injection site. Furthermore, people rarely life-threatening effects. Thus, Iran are safe.

Язык: Английский

---

Impact of comorbidities on hospitalised Syrian patients with COVID-19: a retrospective study

BMJ Open, Год журнала: 2023, Номер 13(3), С. e068849 - e068849

Опубликована: Март 1, 2023

Objectives This study aims to compare the clinical manifestations, laboratory findings, outcomes and overall survival time of patients with COVID-19 without comorbidities. Design Retrospective design. Setting was undertaken at two hospitals in Damascus. Participants A total 515 Syrian met inclusion criterion, laboratory-confirmed infection following Centers for Disease Control Prevention. Exclusion criteria were suspected probable cases that not confirmed a positive reverse transcription-PCR assay, who self-discharged from hospital against medical advice. Primary secondary outcome measures First, assess impacts comorbidities on four areas (clinical severity outcomes). Second, calculate Results Of included, 316 (61.4%) male 347 (67.4%) had least one coexisting chronic disease. Patients compared no more vulnerable poor such as severe (32.0% vs 9.5%, p<0.001), complications (34.6% need mechanical ventilation (28.8% 7.7%, p<0.001) death 8.3%, p<0.001). Multiple logistic regression showed age ≥65 years old, smoking history, having ≥2 obstructive pulmonary disease risk factors linked Overall lower among (vs comorbidities), comorbidity), hypertension, disease, malignancy or obesity other comorbidities) (p<0.05). Conclusion revealed those Severe complications, usage prevalent

Язык: Английский

---

Side Effects of COVID-19 Vaccines in Pregnant and Lactating Mexican Women and Breastfed Infants: A Survey-Based Study

Vaccines, Год журнала: 2023, Номер 11(8), С. 1280 - 1280

Опубликована: Июль 25, 2023

COVID-19 vaccines' safety has been extensively studied; however, further analysis is required in pregnant women, nursing mothers, and breastfed infants. Our aim was to compare the extension severity of self-reported vaccine side effects breastfeeding In this cross-sectional study, COVID-19-vaccinated subjects were enrolled using an online survey Mexico. Women classified by pregnancy status at time vaccination (n = 3167). After first or only dose, there a trend toward fewer systemic women (p 0.06). BNT162b2 (Pfizer-BioNTech) had higher frequency local symptoms pregnancy. Lactating experienced after single dose 0.04) opposite occurred second 0.001). ChAdOx1 (AstraZeneca) increased chances developing both but decreased them dose. The similar across groups, although result lack association requires studies with larger sample size. Irritability most reported symptom This study contributes knowledge about lactating babies.

Язык: Английский

---

Side effects of COVID-19 vaccines in the middle eastern population

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Ноя. 3, 2023

The COVID-19 pandemic has caused severe worldwide health concerns since its first description as the SARS-COV-2 virus in December 2019. wide dissemination of this virus, together with lack treatment, prompted vaccine development within a short period time to elicit protective immunity against COVID-19. Due their rapid development, potential subsequent side effects vaccines were overlooked, which might lead many concerns. This is especially true for patients at greater risk harm from COVID-19, such pregnant women, children, and pre-existing chronic diseases. In review, we provide summary common rare administrated Middle Eastern population. We have found that distinction between terms frequency severity attributed differences study populations, gender, age. Pain injection site, fever, headache, fatigue, muscle pain most reported effects. Vaccinated subjects previous infection exhibited an equivalent neutralizing response after just one dose compared two doses vaccine. Consequently, individuals who experienced more had significantly higher antibody levels. indicates having better correlates levels, leading Individuals underlying comorbidities, particularly known allergies illnesses diabetes cancer, be prone post-vaccination Studies high-risk population countries are limited. Future studies should considered determine long-term effects, booster doses, effect cases heterologous homologous vaccination understanding proper handling populations experience these

Язык: Английский

---